Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
McKinsey
Merck
Mallinckrodt
Medtronic

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR TERIPARATIDE RECOMBINANT HUMAN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Teriparatide Recombinant Human

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000400 ↗ Alendronate and/or Parathyroid Hormone for Osteoporosis Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 2 1999-08-01 This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly select postmenopausal women who have osteoporosis to receive laboratory-produced human parathyroid hormone (hPTH), or alendronate, or both for 2.5 years. Study participants will return to the study center periodically to have their bone mass measured and to give blood and urine samples for tests of bone formation and breakdown and for other laboratory tests. Those who complete the study are eligible for one or two 12 month extension studies.
NCT00000400 ↗ Alendronate and/or Parathyroid Hormone for Osteoporosis Completed Massachusetts General Hospital Phase 2 1999-08-01 This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly select postmenopausal women who have osteoporosis to receive laboratory-produced human parathyroid hormone (hPTH), or alendronate, or both for 2.5 years. Study participants will return to the study center periodically to have their bone mass measured and to give blood and urine samples for tests of bone formation and breakdown and for other laboratory tests. Those who complete the study are eligible for one or two 12 month extension studies.
NCT00005006 ↗ Parathyroid Hormone (PTH) With Alendronate for Osteoporosis Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 2 1987-09-01 This study investigates the effectiveness of parathyroid hormone (PTH) in combination with alendronate, a standard treatment for osteoporosis that blocks or reduces bone loss. We are using alendronate because it may help protect patients against any possible harmful effects of PTH in cortical bone such as the long bones or hip. We are testing two different treatment schedules of PTH-one in which we give PTH daily and one in which we give PTH for 3 out of every 6 months in a cyclical fashion. The entire study is 21 months long; the active treatment period is 18 months with a 6-month followup period. The main effects we will look for in this study are changes in body chemicals that are signs of bone formation or bone breakdown, and changes in bone density throughout the skeleton. We will randomly assign all study participants, who are women aged 50 and over, to either stay on alendronate alone, receive daily continuous PTH plus alendronate, or receive daily PTH for 3 months out of every 6 for a total of three separate 3-month cycles of PTH plus daily alendronate.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Teriparatide Recombinant Human

Condition Name

Condition Name for Teriparatide Recombinant Human
Intervention Trials
Osteoporosis 67
Osteoporosis, Postmenopausal 13
Postmenopausal Osteoporosis 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Teriparatide Recombinant Human
Intervention Trials
Osteoporosis 103
Osteoporosis, Postmenopausal 32
Fractures, Bone 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Teriparatide Recombinant Human

Trials by Country

Trials by Country for Teriparatide Recombinant Human
Location Trials
United States 251
Canada 38
Denmark 14
Germany 12
Spain 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Teriparatide Recombinant Human
Location Trials
New York 22
Pennsylvania 13
Massachusetts 13
Georgia 13
Nebraska 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Teriparatide Recombinant Human

Clinical Trial Phase

Clinical Trial Phase for Teriparatide Recombinant Human
Clinical Trial Phase Trials
Phase 4 46
Phase 3 31
Phase 2/Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Teriparatide Recombinant Human
Clinical Trial Phase Trials
Completed 95
Recruiting 16
Unknown status 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Teriparatide Recombinant Human

Sponsor Name

Sponsor Name for Teriparatide Recombinant Human
Sponsor Trials
Eli Lilly and Company 51
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 8
Massachusetts General Hospital 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Teriparatide Recombinant Human
Sponsor Trials
Other 146
Industry 87
NIH 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Boehringer Ingelheim
Harvard Business School
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.